News reporting will resume with coverage of the Conference on Retroviruses and Opportunistic Infections (CROI), being held in San Francisco from 9 to 12 March. Our reporting team from CROI are Keith ...

Ensitrelvir PEP was safe and effective for COVID-19 prevention among household contacts when administered after the onset of symptoms in an index patient.

One of the hot topics at this year's Conference on Retroviruses and Opportunistic Infections will be long COVID: potential causes, biomarkers, and the significance of viral rebound. A virologist ...

This year’s Conference on Retroviruses and Opportunistic Infections (CROI) features several sessions discussing prevention and treatment of viral infections like HIV and COVID-19. The conference ...

Data from a very early-phase trial shows that the drug is safe and remains in the body for up to 56 weeks. From two injections per year to one against HIV. "It is a hopeful step and the study data are ...

A slow immune response to SARS-CoV-2 infection, delayed viral clearance, and viral rebound can all increase a person’s risk ...

Detailed results were presented at the 2025 Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco. "This study brought us a step forward in better understanding mpox disease ...

For household contacts of individuals with COVID-19, taking ensitrelvir within 72 hours of symptoms is effective at preventing infection and generally well tolerated.

Data derived from Fox M, et al. Abstract 204A. Presented at: Conference on Retroviruses and Opportunistic Infections; March 9-12, 2025; San Francisco and Fox M, et al. Abstract 204B. Presented at ...

Previous research has suggested an increased risk for neuropsychiatric symptoms in people living with HIV who are being ...

At the 2025 meeting of the Conference on Retroviruses and Opportunistic Infections (CROI) it was the best of times, it was the worst of times. On the first full day of the conference, reports from the ...

ACTG, a global clinical trials network focused on HIV and other infectious diseases, today presented data demonstrating that switching to an integrase inhibitor-based antiretroviral regimen increased ...